Diabetic atherosclerosis in APOE*4 mice: Synergy between lipoprotein metabolism and vascular inflammation

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 386-396

  Johnson, Lance A ^a   Kim, Hyung Suk ^a   Knudson, Melissa J ^a   Nipp, C Taylor ^a   Yi, Xianwen ^a   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akita mutation; Apolipoproteins; Foam cell plaques; HDL cholesterol; Humanized animal models; Leukocyte recruitment; Macrophage; Reverse cholesterol transport; Type 1 diabetes; VLDL secretion

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B48; APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL;

ALLELES; ANIMALS; APOLIPOPROTEIN E4; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; RECEPTORS, LDL;

EID: 84872476007     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M031435     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. 2011. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA.
2. Kannel, W. B., and D. L. McGee. 1979. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 241: 2035-2038. (Pubitemid 9228506)
3. Grundy, S. M., I. J. Benjamin, G. L. Burke, A. Chait, R. H. Eckel, B. V. Howard, W. Mitch, S. C. Smith, Jr., and J. R. Sowers. 1999. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 100: 1134-1146. (Pubitemid 29416243)
4. Goldberg, I. J. 2001. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Metab. 86: 965-971. (Pubitemid 32322966)
5. Jenkins, A. J., T. J. Lyons, D. Zheng, J. D. Otvos, D. T. Lackland, D. McGee, W. T. Garvey, and R. L. Klein; DCC/EDIC Research Group. 2003. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 26: 810-818. (Pubitemid 36929348)
6. Johnson, L. A., and N. Maeda. 2010. Macrovascular complications of diabetes in atherosclerosis prone mice. Expert Rev. Endocrin. & Metab. 5: 89-98.
7. Hsueh, W., E. D. Abel, J. L. Breslow, N. Maeda, R. C. Davis, E. A. Fisher, H. Dansky, D. A. McClain, R. McIndoe, M. K. Wassef, et al. 2007. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 100: 1415-1427. (Pubitemid 46834754)
8. Renard, C. B., F. Kramer, F. Johansson, N. Lamharzi, L. R. Tannock, M. G. von Herrath, A. Chait, and K. E. Bornfeldt. 2004. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114: 659-668. (Pubitemid 39578756)
9. Wang, J., T. Takeuchi, S. Tanaka, S. K. Kubo, T. Kayo, D. Lu, K. Takata, A. Koizumi, and T. Izumi. 1999. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J. Clin. Invest. 103: 27-37. (Pubitemid 29031160)
10. -/- mice show severely elevated lipid levels and increased therosclerosis: a model of type 1 diabetic macrovascular disease. J. Lipid Res. 52: 1483-1493.
11. Mahley, R. W., and S. C. Rall. 2000. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1: 507-537.
12. Sullivan, P. M., H. Mezdour, Y. Aratani, C. Knouff, J. Najib, R. L. Reddick, S. H. Quarfordt, and N. Maeda. 1997. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272: 17972-17980. (Pubitemid 27306374)
13. Knouff, C., M. E. Hinsdale, H. Mezdour, M. K. Altenburg, M. Watanabe, S. H. Quarfordt, P. M. Sullivan, and N. Maeda. 1999. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103: 1579-1586.
14. Malloy, S. I., M. K. Altenburg, C. Knouff, L. Lanningham-Foster, J. S. Parks, and N. Maeda. 2004. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler. Thromb. Vasc. Biol. 24: 91-97. (Pubitemid 38082417)
15. Jun, J. Y., Z. Ma, and L. Segar. 2011. Spontaneously diabetic Ins2+/ Akita:apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. Am. J. Physiol. Endocrinol. Metab. 301: E145-E154.
16. Knouff, C., S. Malloy, J. Wilder, M. K. Altenburg, and N. Maeda. 2001. Doubling expression of the low density lipoprotein receptor by truncation of the 3′-untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform. J. Biol. Chem. 276: 3856-3862.
17. Johnson, L. A., M. K. Altenburg, R. L. Walzem, L. T. Scanga, and N. Maeda. 2008. Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptorbinding sequences. Arterioscler. Thromb. Vasc. Biol. 28: 1745-1752.
18. de Silva, H. V., J. Mas-Oliva, J. M. Taylor, and R. W. Mahley. 1994. Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse. J. Lipid Res. 35: 1297-1310. (Pubitemid 24209404)
19. Altenburg, M., L. Johnson, J. Wilder, and N. Maeda. 2007. Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner. J. Biol. Chem. 282: 7817-7824. (Pubitemid 47093587)
20. Sparks, J. D., and C. E. Sparks. 1994. Insulin regulation of triacyl-glycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta. 1215: 9-32. (Pubitemid 24345052)
21. Twisk, J., D. L. Gillian-Daniel, A. Tebon, L. Wang, P. H. Barrett, and A. D. Attie. 2000. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105: 521-532.
22. Kamagate, A., and H. H. Dong. 2008. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle. 7: 3162-3170.
23. Hirota, S., M. Imakita, K. Kohri, A. Ito, E. Morii, S. Adachi, H. M. Kim, Y. Kitamura, C. Yutani, and S. Nomura. 1993. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am. J. Pathol. 143: 1003-1008.
24. Matsumoto, S., T. Kobayashi, M. Katoh, S. Saito, Y. Ikeda, M. Kobori, Y. Masuho, and T. Watanabe. 1998. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am. J. Pathol. 153: 109-119. (Pubitemid 28317513)
25. Altenburg, M., J. Arbones-Mainar, L. Johnson, J. Wilder, and N. Maeda. 2008. Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler. Thromb. Vasc. Biol. 28: 1104-1110.
26. Stalenhoef, A. F., M. J. Malloy, J. P. Kane, and R. J. Havel. 1984. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc. Natl. Acad. Sci. USA. 81: 1839-1843. (Pubitemid 14149560)
27. Yokode, M., R. E. Hammer, S. Ishibashi, M. S. Brown, and J. L. Goldstein. 1990. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science. 250: 1273-1275. (Pubitemid 120031843)
28. Cannon, C. P. 2007. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin. Cornerstone. 8 (Suppl. 6) : S14-S23.
29. Goldberg, I. J., A. Isaacs, E. Sehayek, J. L. Breslow, and L. S. Huang. 2004. Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis. 172: 47-53. (Pubitemid 38058600)
30. Kako, Y., M. Massé, L. S. Huang, A. R. Tall, and I. J. Goldberg. 2002. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J. Lipid Res. 43: 872-877. (Pubitemid 34602608)
31. Fonseca, V., C. Desouza, S. Asnani, and I. Jialal. 2004. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr. Rev. 25: 153-175. (Pubitemid 38269978)
32. Chait, A., and K. E. Bornfeldt. 2009. Diabetes and atherosclerosis: is there a role for hyperglycemia? J. Lipid Res. 50: S335-S339.
33. Funk, S. D., A. Yurdagul, Jr., and A. W. Orr. 2012. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int. J. Vasc. Med. 2012: 569654.
34. Dansky, H. M., C. B. Barlow, C. Lominska, J. L. Sikes, C. Kao, J. Weinsaft, M. I. Cybulsky, and J. D. Smith. 2001. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler. Thromb. Vasc. Biol. 21: 1662-1667. (Pubitemid 34215588)
35. Cybulsky, M. I., K. Iiyama, H. Li, S. Zhu, M. Chen, M. Iiyama, V. Davis, J. C. Gutierrez-Ramos, P. W. Connelly, and D. S. Milstone. 2001. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107: 1255-1262. (Pubitemid 32494542)
36. Tang, C., J. E. Kanter, K. E. Bornfeldt, R. C. Leboeuf, and J. F. Oram. 2010. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J. Lipid Res. 51: 1719-1728.
37. Parathath, S., L. Grauer, L. S. Huang, M. Sanson, E. Distel, I. J. Goldberg, and E. A. Fisher. 2011. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes. 60: 1759-1769.
38. Lucic, D., Z. H. Huang, D. S. Gu, M. K. Altenburg, N. Maeda, and T. Mazzone. 2007. Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor. J. Lipid Res. 48: 366-372. (Pubitemid 46220603)
39. Cullen, P., A. Cignarella, B. Brennhausen, S. Mohr, G. Assmann, and A. von Eckardstein. 1998. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J. Clin. Invest. 101: 1670-1677. (Pubitemid 28198496)
40. Hara, M., T. Matsushima, H. Satoh, N. Iso-o, H. Noto, M. Togo, S. Kimura, Y. Hashimoto, and K. Tsukamoto. 2003. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler. Thromb. Vasc. Biol. 23: 269-274. (Pubitemid 36231939)
41. Cash, J. G., D. G. Kuhel, J. E. Basford, A. Jaeschke, T. K. Chatterjee, N. L. Weintraub, and D. Y. Hui. 2012. Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress. J. Biol. Chem. 287: 27876-27884.
42. Nakamuta, M., K. Oka, J. Krushkal, K. Kobayashi, M. Yamamoto, W. H. Li, and L. Chan. 1995. Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related nucleoside/nucleotide deaminases. J. Biol. Chem. 270: 13042-13056.
43. Versmissen, J., D. M. Oosterveer, M. Hoekstra, R. Out, J. F. Berbée, A. C. Blommesteijn-Touw, L. van Vark-van der Zee, R. Vongpromek, T. Vanmierlo, J. C. Defesche, et al. 2011. Apolipoprotein isoform E4 does not increase coronary heart disease risk in carriers of lowdensity lipoprotein receptor mutations. Circ. Cardiovasc. Genet. 4: 655-660.